Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients
- PMID: 21389143
- DOI: 10.1210/jc.2010-2708
Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients
Abstract
Purpose: This prospective study evaluated the recurrence rate in 715 patients with differentiated thyroid cancer who had no evidence of persistent disease after total thyroidectomy and lymph node dissection in 94% of them followed up by radioiodine ablation (30-100 mCi) and assessed the predictive value of the initial thyroglobulin (Tg) levels for detecting recurrence, both during levothyroxine (LT4) treatment and after TSH stimulation.
Patients and methods: Patients had Tg determinations performed at 3 months on LT4 treatment (Tg1) and at 9-12 months after stimulation by either thyroid hormone withdrawal or recombinant human TSH (Tg2); the Access kit was used (functional sensitivity of 0.11 ng/ml); they had undetectable anti-Tg antibodies. Patients were followed up annually. Predictive values were calculated by comparing Tg levels (Tg1 and Tg2) and the outcome in terms of recurrence.
Results: During the median follow-up of 6.2 yr, 32 patients had a recurrence. Assuming a cutoff level for Tg1 at 0.27 ng/ml, Tg1 sensitivity and specificity reached 72 and 86%, respectively, whereas predictive positive and negative values were 20 and 99%, respectively. With a cutoff level for Tg2 at 1.4 ng/ml, sensitivity and specificity reached 78 and 90%, respectively, whereas positive and negative predictive values were 26 and 99%, respectively.
Conclusion: This large prospective cohort of patients presented a low rate of recurrence. Initial Tg measurements allow to predict long-term recurrence with an excellent specificity. Stimulated Tg determination presented a slightly higher sensitivity than Tg determination on LT4. TSH stimulation may be avoided when Tg measured 3 months after ablation is less than 0.27 ng/ml during LT4 treatment.
Similar articles
-
Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level.Endocr Relat Cancer. 2011 Mar 3;18(2):R29-40. doi: 10.1677/ERC-10-0292. Print 2011 Apr. Endocr Relat Cancer. 2011. PMID: 21183629 Review.
-
Prevalence, clinical significance and prognostic value of anti-thyroglobulin antibodies in the follow-up of patients with differentiated thyroid carcinoma: a retrospective study.Minerva Endocrinol. 2009 Sep;34(3):195-203. Minerva Endocrinol. 2009. PMID: 19859043
-
Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients.J Clin Endocrinol Metab. 2007 Jul;92(7):2487-95. doi: 10.1210/jc.2006-0723. Epub 2007 Apr 10. J Clin Endocrinol Metab. 2007. PMID: 17426102 Clinical Trial.
-
Follow-up of differentiated thyroid carcinoma.Minerva Endocrinol. 2004 Dec;29(4):161-74. Minerva Endocrinol. 2004. PMID: 15765026 Review. English, Italian.
-
Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?J Clin Endocrinol Metab. 2002 Apr;87(4):1490-8. doi: 10.1210/jcem.87.4.8338. J Clin Endocrinol Metab. 2002. PMID: 11932270
Cited by
-
The value of the first postoperative diagnostic I-131 scan in patients with papillary thyroid carcinoma.J Cancer Res Clin Oncol. 2024 Feb 6;150(2):80. doi: 10.1007/s00432-023-05581-6. J Cancer Res Clin Oncol. 2024. PMID: 38319395 Free PMC article.
-
Translocated HMGB3 is involved in papillary thyroid cancer progression by activating cytoplasmic TLR3 and transmembrane TREM1.Cell Cycle. 2023 Dec-Dec;22(23-24):2584-2601. doi: 10.1080/15384101.2024.2302244. Epub 2024 Jan 10. Cell Cycle. 2023. PMID: 38197217
-
Clinical prediction models for cervical lymph node metastasis of papillary thyroid carcinoma.Endocrine. 2024 May;84(2):646-655. doi: 10.1007/s12020-023-03632-z. Epub 2024 Jan 4. Endocrine. 2024. PMID: 38175390
-
Impact of Additional Preoperative Computed Tomography Imaging on Staging, Surgery, and Postsurgical Survival in Patients With Papillary Thyroid Carcinoma.Korean J Radiol. 2023 Dec;24(12):1284-1292. doi: 10.3348/kjr.2023.0240. Korean J Radiol. 2023. PMID: 38016686 Free PMC article.
-
Analysis of the clinical factors affecting excellent response of Iodine-131 treatment for pulmonary metastases from differentiated thyroid cancer.Heliyon. 2023 Oct 13;9(11):e20853. doi: 10.1016/j.heliyon.2023.e20853. eCollection 2023 Nov. Heliyon. 2023. PMID: 37928010 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous